A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
Read time: 1 mins
Last updated:20th Nov 2012
To compare progression-free survival in patients with HER1- and/or HER2-overexpressing stage IV bladder cancer who have been randomized to maintenance therapy with lapatinib ditosylate or placebo following first-line chemotherapy.
|Study start date||2012-11-20|